The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of amrubicin (AMR) and cyclophosphamide in patients with advanced solid organ malignancies: A trial from the Hoosier Oncology Group.
S. I. Jalal
No relevant relationships to disclose
J. A. Bufill
No relevant relationships to disclose
G. A. Masters
No relevant relationships to disclose
N. Somaiah
No relevant relationships to disclose
K. Koneru
No relevant relationships to disclose
J. McClean
No relevant relationships to disclose
R. E. Sanborn
No relevant relationships to disclose
J. Wu
No relevant relationships to disclose
Z. Yu
No relevant relationships to disclose
L. H. Einhorn
Consultant or Advisory Role - Celgene